Fzata, Inc.
- Hanping Feng
Hanping Feng has a strong academic background and extensive experience in the field of scientific research. Hanping is currently serving as the Chief Scientific Officer at FZata, Inc., a position they have held since May 2019. Prior to that, Hanping worked as a Professor at the University of Maryland Baltimore, where they held the position of Associate Professor from 2012 to 2015 and then progressed to the role of Professor. Before their time at the University of Maryland, Hanping worked at Tufts University as an Associate Professor from 2009 to 2011, and as a Research Assistant Professor from 2004 to 2009. Hanping also gained valuable experience as a Postdoc at Harvard Medical School from 2002 to 2004. Throughout their career, Hanping has demonstrated their expertise in scientific research and academia, making him a valuable asset to any organization.
Hanping Feng earned a Doctor of Philosophy (PhD) degree in Microbiology and Immunology from the University of Arizona, where they studied from 1999 to 2002.
Org chart
Upgrade to view 1 report
Teams
This person is not in any teams
Offices
This person is not in any offices
Fzata, Inc.
Fzata’s capturing the “holy grail” of oral biologics with our transformational Bioengineered Probiotic Yeast Medicines (BioPYM) modality. With $17M in non-dilutive NIH funding, Fzata has developed a pipeline of drug candidates for gastrointestinal-related disorders. BioPYM platform uses live yeast as a ‘factory’ to make recombinant therapeuticbiologics in the gut. Advantages over traditional biologics include: simple yeast manufacturing, no anti-drug antibody response, no toxicity, no refrigeration and no needles. BioPYM FZ002 first-in-human phase 1 clinical trial. for C. diff infection will be in 2023. Next is FZ006 for ulcerative colitis and Crohn's disease.
